Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.28+0.09 (+0.88%)
Close on Nov 13, 2026Market cap $661.57MP/E –Yield –
Cullinan Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cullinan Therapeutics's price to sales ratio was 22.9× on Apr 29, 2022.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Apr 29, 2022 | 22.9× | – |
See a number that looks wrong?